Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Efpeglenatide vs Magnesium: Magnesium has the stronger overall evidence (8.5 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Magnesium wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
12 of 16 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Efpeglenatide and Magnesium have evidence — compare verdict strength side-by-side.
INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
200-350mg elemental magnesium daily
Evening for sleep/relaxation (glycinate), Morning for energy (malate), Anytime (citrate)
Depends on goal - see notes
Over ~1.8 years (trial follow-up)
Over ~1.8 years
Weeks to months
Months (titrated)
1-2 weeks
1-2 weeks
1 week
Immediate
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=4076
Pivotal randomized, placebo-controlled cardiovascular-outcomes trial (n=4,076) at 344 sites in 28 countries, in type 2 diabetes with a history of cardiovascular disease OR current kidney disease plus another risk factor; weekly subcutaneous efpeglenatide 4 or 6 mg vs placebo, median follow-up 1.81 years
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Diabetes Obes Metab (2024) · Observational · n=3983
Prespecified epidemiological analysis of AMPLITUDE-O data (n=3,983 with baseline eGFR/UACR) relating kidney-disease indices to MACE and the composite kidney outcome and testing whether efpeglenatide's effect varies with them
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Diabetes Care (2022) · Rct · n=480
Phase-3 double-blind, placebo-controlled monotherapy RCT in type 2 diabetes inadequately controlled with diet and exercise; once-weekly efpeglenatide 2/4/6 mg vs placebo for up to 56 weeks
Magnesium supplementation in pregnancy
The Cochrane database of systematic reviews (2014) · Meta analysis · n=9090
Women receiving magnesium were significantly less likely to require hospitalisation during pregnancy (RR 0.65, 95% CI 0.48 to 0.86; three trials, 1158 women).Of the 10 trials included in the review, only two were judged to be of high quality overall.
Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis
Hypertension (2025) · Meta analysis · n=2709
38 RCTs with 2709 participants analyzed
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Nutrients (2024) · Meta analysis
Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations.
Based on meta-analysis of 38 RCTs with 2709 participants showing -7.68 mmHg reduction in hypertensive individuals. Effects are greatest in those with hypomagnesemia. Limited evidence in normotensive populations.
AI-estimated from published studies. Interpret as directional guidance.
Magnesium has a higher evidence score (8.5/10 vs 4.3/10) and wins in 3 of 3 categories.
For support heart health, Magnesium has a higher relevance score (75 vs 66).
No known interactions between Efpeglenatide and Magnesium have been documented in our database. However, always consult a healthcare provider before combining supplements.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Tired? Why most "energy" pills only work if they fix a deficit — and how to find yours first.
Berberine, inositol, magnesium vs the cinnamon/chromium hype — and the med-interaction warning.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.